What is seqWell?
Headquartered in Beverly, Massachusetts, seqWell specializes in the development of advanced library construction technologies designed to optimize NGS instrumentation. The company's flagship plexWell technology represents a significant leap in multiplexed library preparation, allowing researchers to achieve unprecedented scale and efficiency. By streamlining application workflows, seqWell addresses the persistent bottlenecks in genomic data production, positioning itself as an essential partner for laboratories and biopharma enterprises seeking to enhance throughput, data quality, and overall utility across diverse sequencing platforms. The firm operates at the intersection of biotechnology and precision diagnostics, providing the foundational tools necessary for modern molecular research.
How much funding has seqWell raised?
seqWell has raised a total of $17.4M across 4 funding rounds:
Private Equity
$1.3M
Series B
$9M
Debt
$150K
Series C
$7M
Private Equity (2016): $1.3M, investors not publicly disclosed
Series B (2020): $9M led by BroadOak Fund and Research
Debt (2020): $150K supported by PPP
Series C (2022): $7M featuring Research, BroadOak Capital Partners, and Codexis
Key Investors in seqWell
Research Corp
Research Corp is a company that operates in the Research & Development industry, providing strategic support to innovative technology firms.
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies.
Codexis
Codexis, Inc. is a leading enzyme engineering company that leverages its proprietary CodeEvolver platform to develop high-performance proteins for therapeutics and diagnostics.
What's next for seqWell?
With this major enterprise-level funding, seqWell is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The strategic focus will likely center on scaling the adoption of the plexWell platform across global markets, while simultaneously refining its suite of library preparation solutions to meet the evolving demands of clinical and research-grade sequencing. As the genomics industry shifts toward higher-volume, cost-sensitive workflows, seqWell's ability to simplify complex processes provides a distinct competitive advantage. Future growth will likely involve expanding its footprint in the biopharma sector, where the demand for high-performance, scalable enzymatic manufacturing and diagnostic tools remains at an all-time high, ensuring the company remains at the forefront of the genomic revolution.
See full seqWell company page
